Literature DB >> 1732556

Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.

J A Montgomery1, A T Shortnacy-Fowler, S D Clayton, J M Riordan, J A Secrist.   

Abstract

The synthesis of 2-halo-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenines (4b and 4d) by coupling the 2,6-dihalopurine with 3-acetyl-5-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide (2) followed by replacement of the 6-halogen with concomitant removal of the acyl blocking groups is described. 2-Fluoroadenine derivative 4g had to be prepared by the diazotization-fluorination of 2-aminoadenine nucleoside 4e. All three nucleosides provided good increases in life span of mice inoculated with P388 leukemia. The best results were obtained when the compounds were administered q3h x 8 on days 1, 5, and 9 after implantation of the leukemia cells. The 2',3'-dideoxynucleoside 5b, prepared by deacetylation of 4f and deoxygenation of the resultant 4h followed by removal of the benzoyl group of 5a, was slightly active against HIV in cell culture.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732556     DOI: 10.1021/jm00080a029

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.

Authors:  Edward Agura; Barry Cooper; Houston Holmes; Estil Vance; Robert Brian Berryman; Christopher Maisel; Sandy Li; Giovanna Saracino; Mirjana Tadic-Ovcina; Joseph Fay
Journal:  Oncologist       Date:  2011-01-27

2.  Clofarabine: in pediatric patients with acute lymphoblastic leukemia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.

Authors:  Carlos E Vigil; Wei Tan; George Deeb; Sheila N Sait; Annemarie W Block; Petr Starostik; Elizabeth A Griffiths; James E Thompson; Jessica D Greene; Laurie A Ford; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2013-08-15       Impact factor: 3.156

4.  Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.

Authors:  S Lindemalm; J Liliemark; B S Larsson; F Albertioni
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 5.  Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Authors:  Benigno C Valdez; Borje S Andersson
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

6.  AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Authors:  Todd M Cooper; Todd A Alonzo; Robert B Gerbing; John P Perentesis; James A Whitlock; Jeffrey W Taub; Terzah M Horton; Alan S Gamis; Soheil Meshinchi; Michael R Loken; Bassem I Razzouk
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

7.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

8.  Clofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.

Authors:  Kristin V Ho; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2015-11-24

9.  Use of clofarabine for acute childhood leukemia.

Authors:  A Pession; R Masetti; K Kleinschmidt; A Martoni
Journal:  Biologics       Date:  2010-06-24

10.  Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.

Authors:  Karen E Thudium; Sampa Ghoshal; Gerald J Fetterly; Jason P Den Haese; Adam R Karpf; Meir Wetzler
Journal:  Leuk Res       Date:  2012-08-09       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.